Skip to main content
SpringerLink
Log in
Book cover

Die Infektiologie pp 75–207Cite as

Antiinfektive Therapie

  • Chapter

  • 359 Accesses

Zusammenfassung

Die antimikrobielle Chemotherapie ist definiert als eine selektiv auf den Erreger wirkende Zerstörung oder Wachstumshemmung unter weitgehender Schonung der körpereigenen Zelle. Eine Trennung in die synthetisch gewonnenen Chemotherapeutika und die von Pilzen oder Bakterien gebildeten Antibiotika ist heute nicht mehr strikt aufrecht zu erhalten, da zahlreiche Antibiotika voll- oder halbsynthetisch hergestellt werden. Die Einteilung erfolgt nach der chemischen Struktur in Substanzgruppen mit meist ähnlichem Verhalten hinsichtlich Wirkungsmechanismus, Wirkungsspektrum, Erregerpersistenz und Toxizität.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   349.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

Allgemeine Literatur zur Resistenzentwicklung

  • Russel AD, Chopra I (1996) Understanding antibacterial action and resistance, 2nd edn. Ellis Horwood, London

    Google Scholar 

  • Yu VL et al. (1999) Antimicrobial therapy and vacines. Williams&Wilkins, Baltimore

    Google Scholar 

Zitierte Übersichts-und Forschungsartikel

  1. Abraham EP, Chain E (1940) An encyme from bacteria able to destroy penicillin. Nature 146:837

    Article  CAS  Google Scholar 

  2. Panlilio AL (1991) MRSA Staphylococcus aureus in U.S. hospitals, 1975–1991. Infect Control Hosp Epidemiol 13:582–586

    Article  Google Scholar 

  3. Kresken M, Hafner D (1999) Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975–1995) Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Infection 27(Suppl 2): S2–S8

    Article  PubMed  Google Scholar 

  4. Schweitzer, Walther T, Uraske J, Osswald PM (1997) Infektionsmanagement in der Operativen Intensivmedizin — Bekämpfung und Prävention von MRSA-Epidemien durch routinemäßiges mikrobiologisches Monitoring und Einsatz von Mupirocin-Nasensalbe. Intensivmedizin 34:778–789

    Article  Google Scholar 

  5. Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134:298–314

    PubMed  CAS  Google Scholar 

  6. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727–737

    PubMed  CAS  Google Scholar 

  7. Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260

    Article  PubMed  CAS  Google Scholar 

  8. Tomasz A (1986) Penicillin-binding proteins and the antibacterial effectiveness of beta-lactam antibiotics. Rev Infect Dis 8 Suppl 3:S260–S278

    Article  Google Scholar 

  9. Spratt BG (1980) Biochemical and genetical approaches to the mechanism of action of penicillin. Philos Trans R Soc London Ser B Biol Sci 289:273–283

    Article  CAS  Google Scholar 

  10. Maidhof H, Johannsen L, Labischinski H, Giesbrecht P (1989) Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent. J Bacteriol 171:2252–2257

    PubMed  CAS  Google Scholar 

  11. Tomasz A, Albino A, Zanati E (1970) Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 227:138–140

    Article  PubMed  CAS  Google Scholar 

  12. Shah PM, Troche G, Stille W (1979) Effect of concentration on bactericidal activity of cefotaxime. J Antimicrob Chemother 5:419–422

    Article  PubMed  CAS  Google Scholar 

  13. Gillespie SH (2002) Evolution of Drug Resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46:267–274

    Article  PubMed  CAS  Google Scholar 

  14. Upcroft PJ, Upcroft A (2001) Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 14:150–164

    Article  PubMed  CAS  Google Scholar 

  15. Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–517

    PubMed  CAS  Google Scholar 

  16. Geerts S, Gryseels B (2000) Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 13:207–222

    Article  PubMed  CAS  Google Scholar 

  17. Fluit AC, Visser MR, Schmitz FJ (2001) Molecular detection of antimicrobial resistance. Clin Microbiol Rev 14:836–871, table

    Article  PubMed  CAS  Google Scholar 

  18. Jenks PJ, Labigne A, Ferrero RL (1999) Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice. Antimicrob Agents Chemother 43:777–781

    Article  PubMed  CAS  Google Scholar 

  19. Wiedemann B (2000) Mechanismen und Epidemiologie der Antibiotikaresistenz. Internist (Berl) 41:1205–1211

    Article  CAS  Google Scholar 

  20. Nikaido H (1994) Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382–388

    Article  PubMed  CAS  Google Scholar 

  21. Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340:517–523

    Article  PubMed  CAS  Google Scholar 

  22. Waldvogel FA (1999) New resistance in Staphylococcus aureus. N Engl J Med 340:556–557

    Article  PubMed  CAS  Google Scholar 

  23. Geisel R, Schmitz FJ, Fluit AC, Labischinski H (2001) Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 20:685–697

    Article  PubMed  CAS  Google Scholar 

  24. Ball PR, Shales SW, Chopra I (1980) Plasmid-mediated tetracycline resistance in Escherichia coli involves increased efflux of the antibiotic. Biochem Biophys Res Commun 93:74–81

    Article  PubMed  CAS  Google Scholar 

  25. McMurry L, Petrucci RE Jr, Levy SB (1980) Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci USA 77:3974–3977

    Article  PubMed  CAS  Google Scholar 

  26. Paulsen IT, Brown MH, Skurray RH (1996) Proton-dependent multidrug efflux systems. Microbiol Rev 60:575–608

    PubMed  CAS  Google Scholar 

  27. Poole K (2000) Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother 44:2595–2599

    Article  PubMed  CAS  Google Scholar 

  28. Putman M, van Veen HW, Konings WN (2000) Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 64:672–693

    Article  PubMed  CAS  Google Scholar 

  29. Van Bambeke F, Balzi E, Tulkens PM (2000) Antibiotic efflux pumps. Biochem Pharmacol 60:457–470

    Article  PubMed  Google Scholar 

  30. Heep M, Odenbreit S, Beck D et al. (2000) Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob Agents Chemother 44:1713–1715

    Article  PubMed  CAS  Google Scholar 

  31. Heep M, Rieger U, Beck D, Lehn N (2000) Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 44:1075–1077

    Article  PubMed  CAS  Google Scholar 

  32. Heep M, Beck D, Bayerdörffer E, Lehn N (1999) Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 43:1497–1499

    PubMed  CAS  Google Scholar 

  33. Vester B, Douthwaite S (2001) Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 45:1–12

    Article  PubMed  CAS  Google Scholar 

  34. Hulten K, Gibreel A, Skold O, Engstrand L (1997) Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 41:2550–2553

    PubMed  CAS  Google Scholar 

  35. Johnson AP, Tysall L, Stockdale MW et al (2002) Emerging linezolidresistant enterococcus faecalis and enterococcus faecium isolated from two austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 21:751–754

    Article  PubMed  CAS  Google Scholar 

  36. Pai MP, Rodvold KA, Schreckenberger PC et al (2002) risk factors associated with the development of infection with linezolid-and vancomycin-resistant enterococcus faecium. Clin Infect Dis 35:1269–1272

    Article  PubMed  Google Scholar 

  37. Auckland C, Teare L, Cooke F et al (2002) Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50:743–746

    Article  PubMed  CAS  Google Scholar 

  38. Gonzales RD, Schreckenberger PC, Graham MB et al (2001) Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179

    Article  PubMed  CAS  Google Scholar 

  39. Wiedemann B, Heisig P (1994) Mechanisms of quinolone resistance. Infection 22 Suppl 2:S73–S79

    Google Scholar 

  40. Berger-Bachi B (1994) Expression of resistance to methicillin. Trends Microbiol 2:389–393

    Article  PubMed  CAS  Google Scholar 

  41. Roberts MC, Sutcliffe J, Courvalin P et al. (1999) Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43:2823–2830

    PubMed  CAS  Google Scholar 

  42. Noble WC, Virani Z, Cree RG (1992) Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72:195–198

    Article  PubMed  CAS  Google Scholar 

  43. Srinivasan A, Dick JD, Perl TM (2002) Vancomycin resistance in staphylococci. Clin Microbiol Rev 15:430–438

    Article  PubMed  CAS  Google Scholar 

  44. CDC (2002) Staphylococcus aureus resistant to vancomycin — United States, 2002) MMWR Morb Mortal Wkly Rep 51:565–567

    Google Scholar 

  45. CDC (2002) Vancomycin-resistant Staphylococcus aureus — Pennsylvania, 2002) MMWR Morb Mortal Wkly Rep 51:902

    Google Scholar 

  46. Stan HJ, Heberer T, Linkerhäger M (1994) Vorkommen von Clofibrinsäure im aquatischen System — Führt die therapeutische Anwendung zu einer Belastung von Oberflächen-, Grund-und Trinkwasser? Vom Wasser 83:57–68

    CAS  Google Scholar 

  47. Feuerpfeil I, Löpez-Pila J, Schmidt R et al. (1999) Antibiotikaresistente Bakterien und Antibiotika in der Umwelt. Bundesgesundheitsblatt — Gesundheitsforschung — Gesundheitsschutz 42:37–50

    Article  Google Scholar 

  48. Livermore DM (1995) Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584

    PubMed  CAS  Google Scholar 

  49. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211–1233

    PubMed  CAS  Google Scholar 

  50. Paterson DL, Ko WC, von Gottberg A et al (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206–2212

    Article  PubMed  CAS  Google Scholar 

  51. Gold HS, Moellering RC Jr (1996) Antimicrobial-drug resistance. N Engl J Med 335:1445–1453

    Article  PubMed  CAS  Google Scholar 

  52. Arakawa Y, Murakami M, Suzuki K et al (1995) A novel integron-like element carrying the metallo-beta-lactamase gene blalMP. Antimicrob Agents Chemother 39:1612–1615

    PubMed  CAS  Google Scholar 

  53. Martinez FD, Holt PG (1999) Role of microbial burden in aetiology of allergy and asthma. Lancet 354 Suppl 2:Sll 12-SII 15

    Google Scholar 

  54. Riedler J, Braun-Fahrlander C, Eder W et al (2001) Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 358:1129–1133

    Article  PubMed  CAS  Google Scholar 

  55. Chuanchuen R, Beinlich K, Hoang TT et al (2001) Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 45:428–432

    Article  PubMed  CAS  Google Scholar 

  56. Drlica K (2001) A strategy for fighting antibiotic resistance. ASM News 67:27–33

    Google Scholar 

  57. Witte W, Klare I (1999) Antibiotikaresistenz bei bakteriellen Infektionserregern. Bundesgesundheitsblatt — Gesundheitsforschung — Gesundheitsschutz 42:8–16

    Article  Google Scholar 

  58. Enne VI, Livermore DM, Stephens P, Hall LM (2001) Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325–1328

    Article  PubMed  CAS  Google Scholar 

  59. Schrag SJ, Perrot V, Levin BR (1997) Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc R Soc London Ser B Biol Sci 264:1287–1291

    Article  CAS  Google Scholar 

  60. Trzcinski K, Hryniewicz W, Claus H, Witte W (1994) Characterization of two different clusters of clonally related methicillin-resistant Staphylococcus aureus strains by conventional and molecular typing. J Hosp Infect 28:113–126

    Article  PubMed  CAS  Google Scholar 

  61. Miller YW, Eady EA, Lacey RW et al. (1996) Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 38:829–837

    PubMed  CAS  Google Scholar 

  62. Seppala H, KlaukkaT, Vuopio-Varkila J et al. (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 337:441–446

    Article  PubMed  CAS  Google Scholar 

  63. Bager F, Aarestrup FM, Madsen M, Wegener HC (1999) Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb Drug Resist 5:53–56

    Article  PubMed  CAS  Google Scholar 

  64. Trouillet JL, Chastre J, Vuagnat A et al (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531–539

    PubMed  CAS  Google Scholar 

  65. Williams RJ, Heymann DL (1998) Containment of antibiotic resistance. Science 279:1153–1154

    Article  PubMed  CAS  Google Scholar 

  66. Haley RW, Bregman DA (1982) The role of understaffing and overcrowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit. J Infect Dis 145:875–885

    Article  PubMed  CAS  Google Scholar 

  67. Gwatkin DR, Guillot M, Heuveline P (1999) The burden of disease among the global poor. Lancet 354:586–589

    Article  PubMed  CAS  Google Scholar 

  68. Okeke IN, Lamikanra A, Edelman R (1999) Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 5:18–27

    Article  PubMed  CAS  Google Scholar 

  69. Hart C, Kariuki AS (1998) Antimicrobial resistance in developing countries. Brit med J 317:647–650

    PubMed  CAS  Google Scholar 

  70. Isturiz RE, Carbon C (2000) Antibiotic use in developing countries. Infect Control Hosp Epidemiol 21:394–397

    Article  PubMed  CAS  Google Scholar 

  71. WHO (1998) Resistance in gonococci isolated in the WHO Western Pacific Region to various antimicrobials used in the treatment of gonorrhoea, 1997. WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme-WHO WPR GASP. Commun Dis Intell 22:288–291

    Google Scholar 

  72. Rowe B, Ward LR, Threlfall EJ (1997) Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 24(Suppl 1):S106–S109

    Article  PubMed  Google Scholar 

  73. Parry C, Wain J, Chinh NT et al. (1998) Quinolone-resistant Salmonella typhi in Vietnam. Lancet 351:1289

    Article  PubMed  CAS  Google Scholar 

  74. Pradier C, Dunais B, Carsenti-Etesse H, Dellamonica P (1997) Pneumococcal resistance patterns in Europe. Eur J Clin Microbiol Infect Dis 16:644–647

    Article  PubMed  CAS  Google Scholar 

  75. Galimand M, Guiyoule A, Gerbaud G et al (1997) Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337:677–680

    Article  PubMed  CAS  Google Scholar 

  76. Gambarotto K, Ploy MC, Dupron F et al. (2001) Occurrence of vancomycin-resistant enterococci in pork and poultry products from a cattle-rearing area of France. J Clin Microbiol 39:2354–2355

    Article  PubMed  CAS  Google Scholar 

  77. Wise R, Hart T, Cars O et al. (1998) Antimicrobial resistance. Is a major threat to public health. Brit med J 317:609–610

    PubMed  CAS  Google Scholar 

  78. Wegener HC (1998) Historical yearly usage of glycopeptides for animals and humans: the American-European paradox revisited. Antimicrob Agents Chemother 42:3049

    PubMed  CAS  Google Scholar 

  79. Bundesgesundheitsblatt (1999) Konferenz der Europäischen Union zur »Bedrohung durch Mikroorganismen« (Kopenhagen, 9.-10. Sept. 1998). Bundesgesundheitsblatt — Gesundheitsforschung — Gesundheitsschutz 42:35–36

    Article  Google Scholar 

  80. Froom J, Culpepper L, Jacobs M et al (1997) Antimicrobials for acute otitis media?. A review from the International Primary Care Network. Brit med J 315:98–102

    PubMed  CAS  Google Scholar 

  81. Norrby SR (1990) Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis 12:458–467

    Article  PubMed  CAS  Google Scholar 

  82. Watson RL, Dowell SF, Jayaraman M et al (1999) Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, parent beliefs. Pediatrics 104:1251–1257

    Article  PubMed  CAS  Google Scholar 

  83. Lemmen SW, Hafner H, Kotterik S et al. (2000) Influence of an infectious disease service on antibiotic prescription behavior and selection of multiresistant pathogens. Infection 28:384–387

    Article  PubMed  CAS  Google Scholar 

  84. Classen DC, Evans RS, Pestotnik SL et al. (1992) The timing of prophylactic administration of antibiotics and the risk of surgicalwound infection. N Engl J Med 326:281–286

    Article  PubMed  CAS  Google Scholar 

  85. Kollef MH, Vlasnik J, Sharpless L et al.(1997) Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 156:1040–1048

    PubMed  CAS  Google Scholar 

  86. Helmuth R (1999) Leitthema Antibiotikaresistenz: Einsatz antimikrobiell wirksamer Substanzen in der Veterinärmedizin. Bundesgesundheitsblatt —Gesundheitsforschung — Gesundheitsschutz 42:26–34

    Article  Google Scholar 

  87. Schrag SJ, Beall B, Dowell SF (2000) Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 13:588–601

    Article  PubMed  CAS  Google Scholar 

  88. CDC (1997) Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Recomm Rep 46:1–24

    Google Scholar 

  89. Shinefield H, Black S, Fattom A et al (2002) Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346:491–496

    Article  PubMed  Google Scholar 

  90. Wong CS, Jelacic S, Habeeb RL et al. (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. N Engl J Med 342:1930–1936

    Article  PubMed  CAS  Google Scholar 

  91. Huppertz HI, Rutkowski S, Busch DH et al. (1999) Bovine colostrum ameliorates diarrhea in infection with diarrheagenic Escherichia coli, shiga toxin-producing E. coli, and E. coli expressing intimin and hemolysin. J Pediatr Gastroenterol Nutr 29:452–456

    Article  PubMed  CAS  Google Scholar 

  92. Erhard MH, Gobel E, Lewan B et al. (1997) Systemic availability of bovine immunoglobulin G and chicken immunoglobulin Y after feeding colostrum and whole egg powder to newborn calves. Arch Tierernähr 50:369–380

    PubMed  CAS  Google Scholar 

  93. Robert Koch-Institut — RKI (2001) www.rki.de

  94. Fitzner J, Kappstein I, Dziekan G, Gastmeier P, et al. (2000) Hygiene methods for patients with methicillin-resistant Staphylococcus aureus (MRSA). Dtsch Med Wochenschr 125:368–371

    PubMed  CAS  Google Scholar 

  95. Struelens MJ, Ronveaux O, Jans B, Mertens R (1996) Methicillin-resistant Staphylococcus aureus epidemiology and control in Belgian hospitals, 1991 to 1995. Groupement pour le Dépistage, l’Etude et la Prévention des Infections Hospitalières. Infect Control Hosp Epidemiol 17:503–508

    Article  PubMed  CAS  Google Scholar 

  96. Farrington M, Trundle C, Redpath C, Anderson L (2000) Effects on nursing workload of different methicillin-resistant Staphylococcus aureus (MRSA) control strategies. J Hosp Infect 46:118–122

    Article  PubMed  CAS  Google Scholar 

  97. Chiosis G, Boneca IG (2001) Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin. Science 293:1484–1487

    Article  PubMed  CAS  Google Scholar 

  98. Schumann C (2002) Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr 41:117–125

    Article  CAS  Google Scholar 

  99. Blaser J, Stone BB, Groner MC, Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergency of resistance. Antimicrob Agents Chemother 31:1054–1070

    PubMed  CAS  Google Scholar 

  100. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  PubMed  CAS  Google Scholar 

  101. Craig WA, Ebert SC (1992) Continuous infusion of ß-lactam antibiotics. Antimicrob Agents Chemother 36:2577–2583

    PubMed  CAS  Google Scholar 

  102. Craig, WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and man.Clin Inf Dis 26:1–12

    Article  CAS  Google Scholar 

  103. Drusano GL, Johnson DE, Rosen M, Standiford HC (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483–490

    PubMed  CAS  Google Scholar 

  104. Drusano GL (1995) Pharmacology of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 4th edn. Churchill Livingstone, New York Edinburgh London, pp 225–233

    Google Scholar 

  105. Eagle H, Musselman AD (1948) The rate of bactericidal action of penicillin in vitro as a function of its concentration and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 88:99–131

    Article  PubMed  CAS  Google Scholar 

  106. Forrest A, Ballow, CH, Nix DE, Birmingham MA, Schentag JJ (1993a) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37:1065–1072

    PubMed  CAS  Google Scholar 

  107. Forrest A, Nix DE, Ballow, CH, Goss, TF, Birmingham MA, Schentag JJ (1993b) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073–1081

    PubMed  CAS  Google Scholar 

  108. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–580

    Article  PubMed  CAS  Google Scholar 

  109. Stahlmann R, Lode H (1998) Concentration-effect relationship of the fluoroquinolones. In: Kuhlmann J, Dalhoff A, Zeiler HJ (eds) Handbook of experimental pharmacology, vol 127. Quinolone antibacterials. Springer, Berlin Heidelberg New York Tokyo, pp 407–420

    Google Scholar 

  110. Wise R (1986) The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 11:470–482

    Article  PubMed  CAS  Google Scholar 

  111. Amsden GW (2000) Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th edn, vol 1. Churchill Livingstone, Philadelphia, pp 572–573

    Google Scholar 

  112. Gilbert DN (2000) Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th edn, vol 1. Churchill Livingstone, Philadelphia, pp 307–336

    Google Scholar 

  113. Kresken M, Zühlsdorf M, Machka K, Hafner D (1996) Zeitliche Entwicklung und aktuelle Resistenzlage bei wichtigen Bakteriengruppen gegenüber Aminoglykosiden. Chemother J 5:54–63

    Google Scholar 

  114. Prins JM, Weverling GJ, deBlok K, van Ketel RJ, Speelman P (1996) Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40:2494–2499

    PubMed  CAS  Google Scholar 

  115. Stahlmann R, Lode H (1986) Welche Faktoren erhöhen die Nephrotoxizität von Aminoglykosid — Antibiotika? Dtsch Med Wochenschr 111:1409–1414

    Article  PubMed  CAS  Google Scholar 

  116. Standiford HC (2000) Tetracyclines and chloramphenicol. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th edn, vol 1. Churchill Livingstone, Philadelphia, pp 336–348

    Google Scholar 

  117. Kucers A, Crowe SM, Grayson ML, Hoy JF (eds) (1997) Tetracyclines. In: The use of antibiotics, 5th edn. Butterworth-Heinemann, Oxford, pp 719–762

    Google Scholar 

  118. Donders GG (2000) Treatment of sexually transmitted bacterial diseases in pregnant women. Drugs 59:477–485

    Article  PubMed  CAS  Google Scholar 

  119. Finegold SM (2000) Metronidazole. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 5th edn, vol 1. Churchill Livingstone, Philadelphia, pp 361–366

    Google Scholar 

  120. Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole. A therapeutic review and update. Drugs 54/5:679–708

    Article  PubMed  CAS  Google Scholar 

  121. Lamp KC, Freeman, CD, Klutman, NE, Lacy MK (1999) Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36:353–373

    Article  PubMed  CAS  Google Scholar 

  122. Adam D (2003) Streptokokken (Gruppe A)-Infektionen. Handbuch DGPI, 4. Aufl. Futuramed Verlag, München, S 648–654

    Google Scholar 

  123. Adam D, Scholz H (1995) Therapie der A-Streptokokken-Tonsillopharyngitis mit Erythromycin-Estolat (5 Tage) versus Penicillin V (10 Tage). Kinderarzt 26:1163–1168

    Google Scholar 

  124. Boyer KM (1998) Nonbacterial pneumonia. In: Feigin RB, Cherry JD(eds) Textbook of pediatric infectious diseases, 4th edn. Saunders, Philadelphia, pp 260–273

    Google Scholar 

  125. Bright GM, Nagel AA, Bordnre J et al. (1988) Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin. A derivate, a new class of macrolide antibiotics, the azalides. J Antibiot 41:1029–1047

    PubMed  CAS  Google Scholar 

  126. Bryskier AJ, Butzler JP, Neu HC et al. (1993) Macrolides. Chemistry, pharmacology and clinical uses. Arnette Blackwell, Paris

    Google Scholar 

  127. Casiano RR (1991) Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 91(Suppl 3A): 275–305

    Google Scholar 

  128. Cross JT, Jacobs RF (1998) Other mycobacteria. In: Feigin RB, Cherry JD: Textbook of pediatric infectious diseases, 4th edn. Saunders, Philadelphia, pp 1239–1249

    Google Scholar 

  129. Dabernat H, Delmas C, Segny M et al. (1991) The activity of clarithromycin and its 14-hydroxy metabolite against H. influenzae, determined by in vitro and serum bacterial test. J Antimicrob Chemother 27(Suppl A): 19–30

    PubMed  CAS  Google Scholar 

  130. Dowell SF, Marcy SM, Philipps WR et al. (1998) Otitis media — principles of joudicious use of antimicrobial agents. Pediatrics 101(Suppl 2):165–170

    Google Scholar 

  131. Dowell SF, Marcy SM, Philipps WR et al. (1985) In vivo sensitivity test in otitis media efficacy of antibiotics. Pediatrics 85:8–18

    Google Scholar 

  132. Drusano GL (1995) Pharmakodynamische Prinzipien bei Antiinfektion und Anwendung für die Bestimmung der Pharmakodynamik von Erythromycinstinoprat im Vergleich zu Erythromycinethylsuccinat. Erysec Symposium; 1995, Sept 30

    Google Scholar 

  133. Ebert S, Rekardstorrit S, Craig WA (1991) Pharmacodynamic comparison of clarithromycin vs erythromycin. In Programm and Abstracts of the 31st Intersc. Conf. Antimicrob. Agents Chemother. Am Ac Microbiol, Washington DC, Abstr 509

    Google Scholar 

  134. Fraschini F, Scaglione F, Pintucci G et al. (1991) The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil und lung in humans. J Antimicrob Chemother 27(Suppl. A):61–65

    PubMed  Google Scholar 

  135. Fujii R, Nishimura T (1988) Pharmakokinetics and clinical evaluation of clarithromycin. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles 1988, Abstr. 648

    Google Scholar 

  136. Haight TH, Finland M (1992) Observations on mode of action of erythromycin. Proc Soc Exp Biol Med 81:181–193

    Google Scholar 

  137. Harris JS, Kolokathis A, Campbell M et al. (1998) Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 17:865–871

    Article  PubMed  CAS  Google Scholar 

  138. Havlir DV, Cube MP, Sattler FR et al. (1996) Prophylaxis against disseminated MAC with azithromycin, daily rifabutin, or both. N Engl J Med 335:392–398

    Article  PubMed  CAS  Google Scholar 

  139. Helwig H (1990) Cholostatische Nebenwirkungen unter Erythromycin. Kinderarzt 21:1292–1295

    Google Scholar 

  140. Hofmann D, Schäfer V, Springklee M (1996) Behandlung von Kindern mit bakteriellen Infektionen der unteren Atemwege. Münchner Med Wochenschr 138:358–363

    Google Scholar 

  141. Hoppe JE, Hahn H, Niethammer D (1995) Umfrage bei niedergelassenen Kinderärzten zur Antibiotikabehandlung bakterieller Infektionen im Kindesalter, I.Angina tonsillaris, Otitis media. Kinderarzt 26:639–643

    Google Scholar 

  142. Kafetzis DA (1987) Efficacy and safety of roxithromycin in treating pediatric patients. J Antimicrob Chemother 20(Supl B):171–177

    PubMed  Google Scholar 

  143. Khenzi B, Segessmann C, Gerber AU (1987) Postantibiotic effect of roxithromycin, erythromycin and clindamycin against selected grampositive bacteria and Haemophilus influenzae. J Antimicrob Chemother 20(Suppl B): 39–46

    Google Scholar 

  144. Klein JO, Bluestone CD (1998) Otitis media. In: Feigin RB, Cherry JD (eds) Textbook of pediatric infectious diseases, 4th edn. Saunders, Philadelphia, pp 195–212

    Google Scholar 

  145. Labro MT, Bryskier A, Babin-Chevage C et al. (1988) Interaction de la roxithromycine avec le polynucléaire neutrophile humain in vitro et in vivo. Pathol Biol 36:711–714

    PubMed  CAS  Google Scholar 

  146. Lambert H (1979) Antimicrobial drugs in the treatment and prevention of pertussis. J Antimicrob Cheomther 5:329–336

    Article  CAS  Google Scholar 

  147. Lode H, Stahlmann R, Wiedemann B (1998) Makrolide. Moderne Antibiotika für Klinik und Praxis. Zett-Verlag, Steinen, S 108; 125-126; 127-128

    Google Scholar 

  148. Malfertheimer P, Beyerdörffer E, Labenz J et al. (1997) Therapie bei peptischen Ulcera. Dtsch Ärztebl 94:C-621-C-627

    Google Scholar 

  149. Maruyama S, Yoshioka H, Fuijita K (1979) Sensitivity of group A-Streptococci to antibiotics. Am J Dis Child 133:1143–1145

    PubMed  CAS  Google Scholar 

  150. Mazzei T, Mini E, Novell A et al. (1993) Chemistry and mode of action of macrolides. J Antimicrob Chemother 21(Suppl): 1–9

    Google Scholar 

  151. McCracken GH (1986) Current status of antibiotic treatment for mycoplasma pneumoniae infections. Pediatr Infect Dis J 5:167–171

    Article  Google Scholar 

  152. O’Brien KL, Dowell SF, Schwautz B et al. (1998) Cough/illness/bronchitis —principles of judicious use of antimicrobial agents. Pediatrics 101 (Suppl.2): 178–181

    Google Scholar 

  153. Pichichero ME (1992) Otitis media, Ped. Asthma. Allerg Immunol 6:167–174

    Google Scholar 

  154. Pichichero ME, Cohen R (1997) Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 16:680–695

    Article  PubMed  CAS  Google Scholar 

  155. Pierce M, Crampton S, Henry D et al. (1996) A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection. N Engl J Med 335:384–391

    Article  PubMed  CAS  Google Scholar 

  156. Pocidado JJ, Vachon F, Coulaud JP et al. (1988) Macrolides et synergistes. Arnette, Paris

    Google Scholar 

  157. Principi N (1995) Multicenter comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in treatment of pediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 14:669–676

    Article  PubMed  CAS  Google Scholar 

  158. Prokexch RC, Hand WL (1982) Antibiotic entry into human polymorphonuclear leucocytes. Antimicob Agents Chemother 21:373–380

    Google Scholar 

  159. Pukander J (1995) Penetration of azithromycin into middle ear effusion in acute and secretory otitis media in children. 19th ICC, Montreal; Abstr 3079

    Google Scholar 

  160. Ramet J (1995) Comparative safety and efficacy of clarithromycin and azithromycin suspensions in the short course treatment of children with acute otitis media. Clin Drug Invest, pp 961–966

    Google Scholar 

  161. Rosenfeld RM, Vertress JE, Carv J (1994) Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5.400 children from thirty-three randomized trials. J Pediatr 124:355–367

    Article  PubMed  CAS  Google Scholar 

  162. Rosenstiel NA von, Adam D, Elies W et al. (1998) Makrolidantibiotika. Ist eine Neubewertung notwendig? Arzneimitteltherapie 16:305–313

    Google Scholar 

  163. Seelis R, DohmenW (1996) Complete ulcer healing without maintenance acid supression after successful 6-day-eradication of Helicobacter pylori-infection. Basic mechanisms to clinical cure. Ottawa

    Google Scholar 

  164. Simon C, Stille W (2000) Antibiotikatherapie in der Klinik und Praxis, 10. Aufl. Schattauer, Stuttgart, S 117–198

    Google Scholar 

  165. Sörgel F, Kinzig-Schipper M, Lauscher R (1996) Erythromycinstinoprat. Dtsch Apotheker Z 136:3107–3113

    Google Scholar 

  166. Stechenberg BW (1998) Borrelia (Lyme disease). In: Feigin RB, Cherry JD (eds) Textbook of pediatric infectious diseases, 4th edn. Saunders, Philadelphia, pp 1522–1515

    Google Scholar 

  167. American Academy of Pediatrics (1997) Antimicrobials and related therapy. In: Peter G (ed) Red Book: Report of the Committee on Infectious Diseases, 24th edn. American Academy of Pediatrics, Elk Grove Village, IL, pp 607–612

    Google Scholar 

  168. Deutsche Gesellschaft für pädiatrische Infektiologie (1997) Handbuch der DGPI (Deutsche Gesellschaft für pädiatrische Infektiologie), 2. Aufl. Futuramed Verlag, München, S. 142

    Google Scholar 

  169. Kasten MJ (1999) Clindamycin, metronidazole and chloramphenicol. Mayo Clin Proc 74, 825–833

    Article  PubMed  CAS  Google Scholar 

  170. Oldach DW, Calia FM (1998) Clindamycin. In: Gorbach SL, Bartlett JG, Blacklow NR (eds) Infectious diseases, 2. Aufl. W.B. Saunders, Philadelphia, pp 232–242

    Google Scholar 

  171. Reese RE, Betts RF (1996) Antbiotic use. In: Reese RE, Betts RF (eds) A practical approach to infectious diseases, 4, Aufl. Little, Brown & Company, Boston New York Toronto London, pp 1262–1268

    Google Scholar 

  172. Rosin H, Henschler D (1996) Antibiotika und Chemotherapeutika. Antiinfektiöse Therapie. In: Forth W, Henschler D, Rummel W, Starke K (Hrsg) Pharmakologie und Toxikologie, 7. Aufl. Spektrum, Heidelberg Berlin Oxford, S 729–731

    Google Scholar 

  173. Scholz H, Mertgen CP (1990) Die Bedeutung der Lincosamid-Antibiotika in der Kinderheilkunde. Z Ärztl Forbild (Jena) 84:1139–1143

    CAS  Google Scholar 

  174. Steigbigel NH (2000) Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 5. edn. Churchill Livingstone, New York, pp 366–382

    Google Scholar 

  175. Allenberger F, Klare I (1999) In vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 43:211–217

    Article  Google Scholar 

  176. Berner R, Heinen F, Pelz K et al. (1997) Ventricular shunt infection due to Bacillus cereus. Neuropedriatics 28:333–334

    Article  CAS  Google Scholar 

  177. Kühnen E, Pfeifer G, Frenkel C (1987) Penetration of fosfomycin into cerebrospinal fluid across non inflamed and inflamed meninges. Infection 15:422–424

    Article  PubMed  Google Scholar 

  178. Alcaide F, Carratala J, Linares J (1996) In vitro activities of eight macrolide antibioties and RP59500 (Quinupristin-Dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Ag Chemother 40:2117–2120

    CAS  Google Scholar 

  179. Barakett V, Lesage DM; Delisle F (1997) Killing kinetics of RP 59500 and pristinamycin against penicillin-resistant pneumococci. Pathol Biol 45:438–440

    PubMed  CAS  Google Scholar 

  180. Bergeron M, Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimcrob Chemother 39 (Suppl A): 129–138

    Google Scholar 

  181. Bernard E, Bensoussan M, Bensoussan F, et al. (1994) Pharmacokinetics and suction blister fluid penetration of a semi-synthetic injectable streptogramin RP 59500 (RP 57669/RP 54476). Eur J Clin Microbiol Infect Dis 13:768–771

    Article  PubMed  CAS  Google Scholar 

  182. Bonilla HF, Perri MB, Kauffman CA (1996) Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Micobiol Infect Dis 25:127–130

    Article  CAS  Google Scholar 

  183. Bryson HM, Spencer CM (1996) Quinupristin-Dalfopristin. Drugs 52:406–415

    Article  PubMed  CAS  Google Scholar 

  184. Chow JW, Davidson A, Sanford II E (1997) Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 24:91–92

    Article  PubMed  CAS  Google Scholar 

  185. Etienne SD, Montay G, Le Liboux A et al. (1992) A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicob Chemother 30(Suppl A): 123–131

    Google Scholar 

  186. Evans PA, Norden CW, Rhoads S et al. (1997) In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicob Ag Chemother 41:1406

    CAS  Google Scholar 

  187. Garcia R, Raad I (1996) In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections. Eur J Clin Microbiol Infect Dis 15:933–936

    Article  PubMed  CAS  Google Scholar 

  188. Herrera-Insua I, Jacques-Palaz K, Murray BE (1996) Intracellular activities of RP 59500 (quinupristin/dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob Ag Chemother 40:886–890

    CAS  Google Scholar 

  189. Lynn WA, Clutterbuck E, Want S et al. (1994) Treatment of CAPD peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 344:1025–1026

    Article  PubMed  CAS  Google Scholar 

  190. Sahgal VS, Urban C, Mariano N et al. (1995) Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report. Micob Drug Res 1:245–247

    Article  CAS  Google Scholar 

  191. Shonekan D, Handwerger S, Mildvan D (1997) Comparative in-vitro activities of RP 59500 (quinupristin/dalfopristin), CL 329, 998, CL 331, 002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against grampositive bacteria. J Antimicob Chemother 39:405–409

    Article  CAS  Google Scholar 

  192. Simon C, Stille W (1999) Antibiotika-Therapie in Klinik und Praxis, 10. Aufl. Schattauer, Stuttgart New York, S 213–215

    Google Scholar 

  193. Torralba MD, Frey SE, Lagging LM (1995) Treatment of methicillin-resistant Staphylococcus aureus infection with quinupristin/dalfopristin. Clin Infect Dis 21:460–461

    Article  PubMed  CAS  Google Scholar 

  194. Levine JF (1987) Vancomycin: A review. Med Clin North Am 71:1135

    PubMed  CAS  Google Scholar 

  195. Cantü T. G, Yamanaka-Yuen NA, Lietman PS (1994) Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 18:533

    Article  PubMed  Google Scholar 

  196. Clark NC, Cooksey RC, Hill BC et al. (1993) Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother 37:2311

    PubMed  CAS  Google Scholar 

  197. Friedland IR, McCracken GH Jr (1994) Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 331:377

    Article  PubMed  CAS  Google Scholar 

  198. Quintiliani R Jr, Evers S, Courvalin P (1993) The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 167:1220

    Article  PubMed  CAS  Google Scholar 

  199. Hayden MK, Koenig GI, Trenholme GM (1994) Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother 38:1225

    PubMed  CAS  Google Scholar 

  200. Glew RH, Keroack MA (1998) Vancomycin und Teicoplanin. Infectious diseases, 2nd edn, pp 260–269

    Google Scholar 

  201. Grose WE, Bodey GP, Loo TL (1979) Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 15:447–451

    PubMed  CAS  Google Scholar 

  202. Perazella MA (2000) Trimethoprim-induced hyperkalemia: clinical data, mechanism, prevention and management. Drug Safety 22:227–236

    Article  PubMed  CAS  Google Scholar 

  203. Zinner SH, Mayer KH (2000) Sulfonamides and Trimethoprim. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, vol 1, 5th edn. Churchill Livingstone, Philadelphia, pp 394–404

    Google Scholar 

  204. Clemett D, Markham A (2000) Linezolid. Drugs 59:815–828

    Article  PubMed  CAS  Google Scholar 

  205. Diekema DJ, Jones, RN (2000) Oxazolidinones. A Review. Drugs 59:7–16

    Article  PubMed  CAS  Google Scholar 

  206. Mulazimoglu L, Drenning SD, Yu VL (1996) In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus epidermidis. Antimicrob Agents Chemother 40:2428–2430

    PubMed  CAS  Google Scholar 

  207. US Fachinformation ZYVOX, Pharmacia Upjohn, April 2000

    Google Scholar 

  208. Andriole VT (1999) The future of the quinolones. Drugs 58(Suppl. 2):1–5

    Article  PubMed  CAS  Google Scholar 

  209. Bressolle F, Goncalves F, Gouby A, Galtier M (1994) Pefloxacin clinical pharmacokinetics. Clin Pharmacokinet 27:418–446

    Article  PubMed  CAS  Google Scholar 

  210. Burkhardt JE, Walterspiel JN, Schaad UB (1997) Quinolone arthropathy in animais versus children. Clin Infect Dis 25:1196–1204

    Article  PubMed  CAS  Google Scholar 

  211. Christ W, Esch B (1994) Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract 3(Suppl 3): 168–176

    Article  Google Scholar 

  212. Christ W, Kemmler H, Esch B (1998) Verträglichkeit und Anwendungssicherheit von Fluorchinolonen. Spezifische toxikologische Aspekte und Nebenwirkungen. In: Adam D, Naber KG (Hrsg) Therapeutische Vergleichbarkeit von Fluorchinolonen. Fortschritte der antimikrobiellen und antineoplstischen Chemotherapie (FAC) 16-1. Futuramed, München, S 85–100

    Google Scholar 

  213. Christ W, Lehnert T (1990) Toxicity of the quinolones. In: Siporin C, Heifetz CL, Domagala JM (eds.). The new generation of quinolones. Marcel Dekker, New York, pp 165–187

    Google Scholar 

  214. Domagala JM (1994) Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33:685–706

    Article  PubMed  CAS  Google Scholar 

  215. Drlica K (1999) Refining the fluoroquinolones. ASM News 65:410–415

    Google Scholar 

  216. Ednie LM, Jacobs MR, Appelbaum PC (1999) Clinafloxacin antibacterial activity. Drugs 58(Suppl 2): 217–221

    Article  CAS  Google Scholar 

  217. Geliert M, Mizuuchi K, O’Dea MH, Itoh T, Tomizawa Jl (1977) Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sei USA 74:4772–4776

    Article  Google Scholar 

  218. Goss WA, Deitz WH, CookTM (1965) Mechanism of action of nalidixic acid on Escherichia coli II. Inhibition of deoxyribonucleic acid synthesis. J Bacteriol 89:1068–1074

    PubMed  CAS  Google Scholar 

  219. Hakanen A, Kotilainen P, Huovinen P et al. (2001) Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from southeast Asia. Emerg Infect Dis 7:996–1003

    Article  PubMed  CAS  Google Scholar 

  220. Hüllen V, Heisig P, Wiedemann B (1999) Induktion des MAR-Phänotyps als mögliche Ursache für die Entwicklung der Fluorchinolon-Re-sistenz bei E. coli. Chemother J 8:79–81

    Google Scholar 

  221. Jafri HS, McCracken jr. GH (1999) Fluoroquinolones in paediatrics. Drugs 58(Suppl 2): 43–48

    Article  PubMed  CAS  Google Scholar 

  222. Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L (1999) In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans Streptococci and genomic organization of the parE-parC region in S.mitis. J Infect Dis 180:555–558

    Article  PubMed  CAS  Google Scholar 

  223. Kashida Y, Kato M (1997) Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother 41:2389–2393

    PubMed  CAS  Google Scholar 

  224. Klecak G, Urbach F, Urwyler H (1997) Fluoroquinolones enhance UVA-induced skin tumors. J Photochem Photobiol B Biol 37:174–181

    Article  CAS  Google Scholar 

  225. Kohler RB, Arkins N, Tack KJ (1991) Accidental overdose of intravenous ofloxacin with benign outcome. Antimicrob Agents Chemother 35:1239–1240

    PubMed  CAS  Google Scholar 

  226. Kresken M, Hafner D (1996) Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa. Chemother J 5:225–230

    Google Scholar 

  227. Kresken M, Hafner D (2000) Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa. Chemother J 9:51–86

    Google Scholar 

  228. Lehmann MH, Hardy S, Archibald D, Mac Neil DJ (1999) JTc prolongation with d,l-Sotalol in women versus men. Am J Cardiol 83:354–359

    Article  PubMed  CAS  Google Scholar 

  229. Lipsky BA, Baker CA (1999) Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis 28:352–364

    Article  PubMed  CAS  Google Scholar 

  230. Lipsky BA, Dorr MB, Magner DJ, Talbot GH (1996) Safety profile of sparfloxacin (SPAR) in North American Phase III clinical trials. 36th ICAAC, September 15-18.1996. New Orleans, Louisiana, Abstract (LO 13)

    Google Scholar 

  231. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590–2597

    Article  PubMed  CAS  Google Scholar 

  232. Maxwell A, Critchlow SE (1998) Mode of Action (Chapter 4). In: Kuhlmann J, Dalhoff A, Zeiler H-J (eds) Quinolone antibacterials. Handbook of experimental pharmacology, Vol. 127. Springer, Berlin Heidelberg New York, pp 119–166

    Google Scholar 

  233. Naber KG, Adam D (1998) Einteilung der Fluorchinolone (PEG-Empfehlungen). Chemother J 7:66–68

    CAS  Google Scholar 

  234. Nicolle LE (1999) Quinolones in the aged. Drugs 58(Suppl 2): 49–51

    Article  PubMed  CAS  Google Scholar 

  235. Shakibaei M, Pfister K, Schwabe R, Vormann J, Stahlmann R (2000) Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 44:261–266

    Article  PubMed  CAS  Google Scholar 

  236. Paton JH, Reeves DS (1991) Clinical features and management of adverse effects of quinolones antibacterials. Drug Safety 6:8–27

    Article  PubMed  CAS  Google Scholar 

  237. Schaad UB, Wedgwood J (1992) Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 30:414–416

    Article  PubMed  CAS  Google Scholar 

  238. Sörgel F, Kinzig-Schippers M, Sauber C, Bulitta J (1999) Pharmakokinetik und Pharmakodynamik von Levofloxacin (Übersicht). Chemother J 8(Suppl. 18): 19–27

    Google Scholar 

  239. Stahlmann R, Förster C, Vormann J (1996) Phototoxizität, Neurotoxizität und Chondrotoxizität der Chinolone: experimentelle Daten und klinische Erfahrungen. In: Lode H, Stille W (Hrsg.) Sparfloxacin bei der Behandlung von ambulant erworbenen tiefen Atemwegsinfektionen. Grundlagen und Standortbestimmung. Fortschritte der antimikrobiellen antineoplastischen Chemotherapie (FAQ 14-1. Futuramed, München, S 193–209

    Google Scholar 

  240. Stahlmann R, Lode H (1998) Nebenwirkungen der neueren Fluorchinolone (Übersicht). Arzneimitteltherapie 16:385–394

    Google Scholar 

  241. Stahlmann R, Lode H (1999) Toxicity of quinolones. Drugs 58(Suppl. 2):37–42

    Article  PubMed  CAS  Google Scholar 

  242. Takayama S, Hirohashi M, Kato M, Shimada H (1995) Toxicity of the quinolone antimicrobial agents (review). J Toxicol Environ Health 45:1–45

    Article  PubMed  CAS  Google Scholar 

  243. Tauchert M (1996) Klinische Relevanz der Auswirkungen von Sparfloxacin auf den Herzrhythmus. In: Lode H, Stille W (Hrsg.). Sparfloxacin bei der Behandlung von ambulant erworbenen tiefen Atemwegsinfektionen — Grundlagen und Standortbestimmung. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie (FAC) 14-1 Futuramed, München, S 187–191

    Google Scholar 

  244. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521–527

    PubMed  CAS  Google Scholar 

  245. Turnidge J (1999) Pharmacokinetics and pharmacodynamics of fluoroquinolones (Review Article). Drugs 58(Suppl. 2): 29–36

    Article  PubMed  CAS  Google Scholar 

  246. von Keutz E, Christ W (1997) Toxicology and safety pharmacology of quinolones. In: Kuhlmann J, Dalhoff A, Zeiler HJ, (eds) Quinolone antibacterials. Handbook of experimental pharmacology, vol 127. Springer, Berlin Heidelberg New York, pp 297–337

    Google Scholar 

  247. von Rosenstiel N, Adam D (1994) Quinolone Antibacterials. An update of their pharmacology and therapeutic use. Drugs 47:872–901

    Article  Google Scholar 

  248. Vormann J, Förster C, Zippel U, Lozo E, Günther T, Merker H-J, Stahlmann R (1997) Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcif Tissue Int 61:230–238

    Article  PubMed  CAS  Google Scholar 

  249. Wiedemann B, Heisig P (1999) Bakterielle Resistenz gegenüber Chinolonen (Ciprofloxacin) (Übersicht). Chemother J 8:99–107

    CAS  Google Scholar 

  250. Adesanya AA, Osegbe DN, Amaku EO (1993) The use of intermittent chlorhexidine bladder irrigation in the prevention of post-prostatectomy infective complications. Int Urol Nephrol 25:359–367

    PubMed  CAS  Google Scholar 

  251. Anderman S, Jaschevatzky DE, Ellenbogen A, Grunstein S (1986) Urinary tract infection after bladder irrigation with povidone-iodine in vaginal surgery. Lancet II: 294

    Article  Google Scholar 

  252. Ball AJ, Carr TW, Gillespie WA, Kelly M, Simpson RA, Smith PJB (1987) Bladder irrigation with chlorhexidine for the prevention of urinary infection after transurethral operations: a prospective controlled study. J Urol 138:491–494

    PubMed  CAS  Google Scholar 

  253. Brühl P, Bootz T (1999) Hygienemaßnahmen in der Urologie. Hofstetter A (Hrsg) Urogenitale Infektionen. Springer, Berlin Heidelberg New York, S 351–369

    Google Scholar 

  254. Brühl P, Schumacher B, Knolle P (1984) PVP-Jod-Harnblasenspülung: Systemische Jodbelastung und Verträglichkeit. Urologe [B] 24:218–222

    Google Scholar 

  255. Brühl P, Widmann T, Sökeland J, Reybrouck G (1986) Nosocomial urinary tract infections: etiology and prevention. Urol Int 41:437–443

    Article  PubMed  Google Scholar 

  256. Chisholm GD (1982) Antimicrobial prophylaxis in urology and transplantation. World J Surg 6:281–292

    Article  PubMed  CAS  Google Scholar 

  257. Cunha BA (1988) Nitrofurantoin — current concepts. Urology 32:67–71

    Article  PubMed  CAS  Google Scholar 

  258. DeVries CR, Freiha FS (1990) Hemorrhagic cystitis: a review. J Urol 143:1–9

    PubMed  CAS  Google Scholar 

  259. Elliott TSJ, Reid L, Gopal Rao G, Rigby RC, Woodhouse K (1989) Bladder irrigation or irritation?. Br J Urol 64:391–394

    Article  PubMed  CAS  Google Scholar 

  260. Flechner SM, McAninch JW (1981) Aspergillosis of the urinary tract: Ascending route of infection and evolving patterns of disease. J Urol 125:598–601

    PubMed  CAS  Google Scholar 

  261. Gasser TC, Madsen PO (1993) Influence of urological irrigation fluids on urothelial bacterial adherence. Urol Res 21:401–405

    Article  PubMed  CAS  Google Scholar 

  262. Giannoni R, Legramandi C, Fonte A (1989) Polyvinilpyrrolidone-lodine (PVP-I) bladder irrigation for prevention of catheter-associated urinary infections in patients treated by TUR. Arch Ital Urol 61:63–67

    CAS  Google Scholar 

  263. Gopal G, Elliott TSJ (1988) Bladder irrigation. Age Ageing (1988) 17:373–378

    Article  Google Scholar 

  264. Hamory BH, Wenzel RP (1978) Hospital associated candiduria: Predisposing factors and review of the literature. J Urol 120:444–448

    PubMed  CAS  Google Scholar 

  265. Harper WES (1981) An appraisal of 12 solutions used for bladder irrigation or instillation. Br J Urol 53:433–438

    Article  PubMed  CAS  Google Scholar 

  266. Hinman F jr, Beizer FO (1969) Urinary tract infection and renal homotransplantation. I. Effect of antibacterial irrigations on defenses of the defunctionalised bladder. J Urol 101:477–481

    PubMed  Google Scholar 

  267. Hofstetter A (1987) Antimikrobielle Wirksamkeit von Gleitmitteln. Urologe [B] 27:359–360

    Google Scholar 

  268. Hsu CCS, Ukleja B (1990) Clearance of Candida colonizing the urinary bladder by a two-day Amphotericin B irrigation. Infection 18:280–282

    Article  PubMed  CAS  Google Scholar 

  269. Hubmann R (1980) Neuere Befunde zur lokalen Anwendung von Polyvi-don-Jod in der Blase. In: Porpaczy P (Hrsg) 1970-1980,10 Jahre Ludwig Boltzmann Institut zur Erforschung der Infektionen und Geschwülste des Harntraktes. Egermann, Wien, S 101–106

    Google Scholar 

  270. Hubmann R, Matz K (1977) Hospitalismusprophylaxe in der Urologie. Urologe [B] 17:223–230

    Google Scholar 

  271. Hubmann R, Hugo K (1984) Klinische Anwendung von PVP-Jod-Komplex in der Urologie (am Beispiel der TUR-P). In: Hierholzer G, Görtz G (Hrsg) PVP-Jod in der operativen Medizin. Springer, Berlin Heidelberg NewYork Tokio, S 110–119

    Google Scholar 

  272. Keller J (1958) Urologie. Steinkopff, Dresden Leipzig

    Google Scholar 

  273. Kierfeld G, Magnus L (1969) Chylurie infolge Filariasis. Urologe 8:314–317

    PubMed  CAS  Google Scholar 

  274. Klebingat K-J, Brühl P, Köhler H (1993) Antiseptik in der Urologie. In: Kramer A, Gröschel D, Heeg P, Hingst V, Lippert H, Rotter M, Weuffen W (Hrsg) Klinische Antiseptik. Springer, Berlin Heidelberg New York, S 201–224

    Google Scholar 

  275. Langkopf B, Ockert G (1979) Parasitäre Erkrankungen des Urogenitalsystems. In: Heise GW, Hienzsch E, Mebel M, Krebs W (Hrsg) Allgemeine und spezielle Urologie, Bd 4. Thieme, Leipzig, S 191–243

    Google Scholar 

  276. Liedl B (1999) Katheterassoziierte Harnwegsinfektionen. In: Hofstetter A (Hrsg) Urogenitale Infektionen. Springer, Berlin Heidelberg New York, S 241–263

    Google Scholar 

  277. Martinez-Garcia F, Regadera J, Mayer R, Sanchez S, Nistal M (1996) Protozoan infections in the male genital tract. J Urol 156:340–349

    Article  PubMed  CAS  Google Scholar 

  278. Michel MC, Wilhelm M (2001) Chlorhexidin als Gleitmittelzusatz. Urologe [B]41:589–590

    Article  Google Scholar 

  279. Michigan S (1976) Genitourinary fungal infection. J Urol 116:390–397

    PubMed  CAS  Google Scholar 

  280. Müssner W, Bösch J, Buhl D, Neuweiler J, Bandhauer K (1997) Filarien: eine Tropenkrankheit als Ursache für das akute Skrotum. Urologe [A] 36:84–86

    Article  Google Scholar 

  281. Muncie HL, Hoopes JM, Damron DJ, Tenney JH, Warren JW (1989) Oncedaily irrigation of long-term urethral catheters with normal saline. Lack of benefit. Arch Intern Med 149:441–443

    Article  PubMed  Google Scholar 

  282. Merimsky E, Werbin N, Canetti R (1981) Pre-operative bladder irrigation with povidone-iodine. Br J Urol 53:330–332

    Article  PubMed  CAS  Google Scholar 

  283. Nöske HD, Kraushaar J, Goetz R (1981) Blasenspülung — Geschichte, Problematik und eigene Erfahrungen. Klinikarzt 10:752–761

    Google Scholar 

  284. Pauer FJ (1954) Erfahrungen mit Varidase, Streptokinase-Streptodornase in der Behandlung urologischer Erkrankungen. Wien Klin Wochenschr 48:924–926

    Google Scholar 

  285. Pearman JW, Bailey M, Harper WES (1988) Comparison of the efficacy of »Trisdine« and kanamycin-colistin bladder instillations in reducing bacteriuria during intermittent catheterisation of patients with acute spinal cord trauma. Br J Urol 62:140–144

    Article  PubMed  CAS  Google Scholar 

  286. Piechota H, Brühl P, Hertle L, Sökeland J (2000) Katheterdrainage der Harnblase heute. Dtsch Ärztebl 97:A-168-174

    Google Scholar 

  287. Rebentisch E (1985) Zur Anwendung von Polyvinylpyrrolidon-Jod-Komplexen (Povidonjod: PVP-Jod). Dtsch Ärztebl 82B: 1434–1436

    Google Scholar 

  288. Robertson MH, Norton MS (1990) Effect of 1 % mandelic acid as a bladder irrigation fluid in patients with indwelling catheters. Br J Clin Pract 44:142–144

    PubMed  CAS  Google Scholar 

  289. Ruwaldt MM (1983) Irrigation of indwelling urinary catheters. Urology 21:127–129

    Article  PubMed  CAS  Google Scholar 

  290. Schmidbauer CP, Porpaczy P (1983) Lokale Anwendung antibakterieller Substanzen in Blase und Harnröhre. Urologe [A] 22:67–75

    CAS  Google Scholar 

  291. Scholtmeijer RJ (1988) Die antiseptische Wirkung von Instillagel bei der Urethro-Zystoskopie von Kindern. Urologe [B] 28:169–170

    Google Scholar 

  292. Sonda LP, Amendola MA (1985) Candida pyocalix: Unusual complication of prolonged nephrostomy drainage. J Urol 134:722–724

    PubMed  CAS  Google Scholar 

  293. Steffens L, Vahlensieck W, Steffens J (1990) Transurethrale Diagnostik und Therapie. Thieme, Stuttgart New York

    Google Scholar 

  294. Stickler DJ (1990) The role of antiseptics in the management of patients undergoing short-term indwelling bladder catheterization. J Hosp Infect 16:89–108

    Article  PubMed  CAS  Google Scholar 

  295. Stöhrer M (1983) Harnwegsinektionen bei neurogener Blasenentleerungsstörung. In: Stille W, Schilling A (Hrsg) Infektionen des Harntraktes. Zuckschwerdt, München Bern Wien, S 112–125

    Google Scholar 

  296. Stöhrer M, Sauerwein D (2001) Der intermittierende Katheterismus bei neurogener Blasenfunktionsstörung. Urologe [B] 41:362–368

    Article  Google Scholar 

  297. Tan L-B, Chiang C-P, Huang C-H, Chou Y-H, Wang C-J (1990) Experiences in the treatment of chyluria in taiwan. J Urol 144:710–713

    PubMed  CAS  Google Scholar 

  298. Vahlensieck W jr (1995) Beeinflussung der Bildung, Festigkeit und Desintegration von Blutgerinnseln durch urologische Spüllösungen und Instillate. Habilitationsschrift Ludwig-Maximilians-Universität München

    Google Scholar 

  299. Vahlensieck W jr (1999) Urogenitalmykosen. In: Hofstetter A (Hrsg) Urogenitale Infektionen. Springer, Berlin Heidelberg New York, S 443–462

    Google Scholar 

  300. Vahlensieck W, Steffens L (1975) Uro-Stilloson zur Behandlung unspezifischer, chronisch-entzündlicher Harnröhren-und Harnblasenaffektionen sowie von Harnröhrenstrikturen. Urologe [B] 15:190–193

    Google Scholar 

  301. Vahlensieck W jr, Schmitz HJ (1999) Parasitäre Urogenitalinfektionen. In: Hofstetter A (Hrsg) Urogenitale Infektionen. Springer, Berlin Heidelberg New York, S 463–505

    Google Scholar 

  302. Vahlensieck W jr, Ott D, Liedl B, Hofstetter A(1993) Epidemiologie, Diagnostik und Therapie der als Raumforderung imponierenden oberen Harnwegsinfektion. Z Urologie Poster 5:44

    Google Scholar 

  303. Van den Broek PJ, Daha TJ, Mouton RP (1985) Bladder irrigation with povidone-iodine in prevention of urinary-tract infections associated with intermittent urethral catheterisation. Lancet 1:563–565

    Article  PubMed  Google Scholar 

  304. Vogel F, von Lilienfeld-Toal H, Exner M, Hamman R (1983) Intravesicale Aminoglykosidinstillation und systemische Antibiotika-Therapie bei Intensivpatienten mit Dauerkatheter. Hyg Med 8:188–192

    Google Scholar 

  305. Wagenknecht LV (1977) Lokale Instillationstherapie bei Zystitiden. In: Die medikamentöse Beeinflussung oxidativer Zellstoffwechselprozesse und ihre klinische Bedeutung. Schnetztor, Konstanz 50–58

    Google Scholar 

  306. Wallnöfer H (1970) Über die Lokalbehandlung mit Nitrofurantoin. Wiener Med Wochenschr 120:577–578

    Google Scholar 

  307. Warren JW, Platt R, Thomas RJ, Rosner B, Kass EH (1978) Antibiotic irrigation and catheter-associated urinary-tract infections. New Engl J Med 299:570–573

    Article  PubMed  CAS  Google Scholar 

  308. Warshawsky AB, Keiller D, Gittes RF (1975) Bilateral renal aspergillosis. J Urol 113:8–11

    PubMed  CAS  Google Scholar 

  309. Waßmann K, Knipper W, Mayr E, Knoke P (1988) Antimikrobielle Wirksamkeit von Gleitmitteln in der Urologie. Urologe [B] 28:367–369

    Google Scholar 

  310. Wise GJ (1998) Fungal infections of the urinary tract. In:. Walsh PC, Retik AB, Vaughan ED jr, Wein AJ (eds) Campbell’s urology, 7th edn, vol 1. Saunders, Philadelphia, pp 779–806

    Google Scholar 

  311. Wise GJ, Kozinn PJ, Goldberg PE (1982) Amphotericin B as a urologic irrigant in the management of non-invasive candiduria. J Urol 128:82–84

    PubMed  CAS  Google Scholar 

  312. Wong-Beringer A, Jacobs A, Guglielmo BJ (1992) Treatment of funguria. JAMA 267:2780–2785

    Article  PubMed  CAS  Google Scholar 

  313. Coukell AJ, Brogden RN (1998) Liposomal Amphotericin B. Drugs 55:585–612

    Article  PubMed  CAS  Google Scholar 

  314. National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A. National Committee for Clinical Laboratory Standards, Wayne/PA

    Google Scholar 

  315. errell CL 1999 Antifungal agents. Part II: The azoles. Mayo Clin Proc 74:78–100

    Article  Google Scholar 

  316. White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382–402

    PubMed  CAS  Google Scholar 

  317. Alberti A, Brunetto MR, Colombo M, Craxi A (2002) Recent progress and new trends in the treatment of hepatitis B. J Med Virol 67:458–462

    Article  PubMed  CAS  Google Scholar 

  318. Albrecht H (1997) Cidofovir. Arzneimitteltherapie 9:267–274

    Google Scholar 

  319. Arzneimittelkommission der Deutschen Ärzteschaft (Hrsg) (2000): Arzneiverordnungen. Kap 4: Virusinfektionen. 19. Aufl. Deutscher Ärzte-Verlag, Köln

    Google Scholar 

  320. Berger A, Preiser W (2002) Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. J Antimicrob Chemother 2002; 49(5): 713–721

    Article  PubMed  CAS  Google Scholar 

  321. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107(3): 812–817

    Article  PubMed  CAS  Google Scholar 

  322. Brockmeyer NH, Salzberger B, Doerr HW, Marcus U, Brodt HR (2001) Antiretrovirale Therapie der HIV-Infektion. Dt Ärztebl 98:A175-181 [Heft 4]

    Google Scholar 

  323. Calfee DP, Hayden FG (1998) New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 56:537–553

    Article  PubMed  CAS  Google Scholar 

  324. Couch RB (2000) Prevention and treatment of influenza (review). N Engl J Med 14;343(24): 1778–1787

    Article  PubMed  CAS  Google Scholar 

  325. Cox NJ, Subbarao K (1999) Influenza. Lancet 354:1277–1282

    Article  PubMed  CAS  Google Scholar 

  326. Crotty S, Cameron CAndino R (2002) Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J Mol Med 80(2) 86–95

    Article  PubMed  CAS  Google Scholar 

  327. De Clercq E (1999) Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 12(2):81–95

    Article  PubMed  Google Scholar 

  328. De Clercq E (2001) Antiviral drugs: current state of the art. J Clin Virol 22(1) 73–89

    Article  PubMed  Google Scholar 

  329. Doerr HW, Mertens T (2000) Virusinfektionen. In: Arzneimittelkommission der Deutschen Ärzteschaft (Hrsg) (2000) Arzneiverordnungen, Kap 4, 19. Aufl. Deutscher Ärzte-Verlag, Köln

    Google Scholar 

  330. Doerr HW, Preiser W, Weber B (1993) Neue Entwicklungen in der antiviralen Chemotherapie. Immun Infekt 21(6):171–176

    PubMed  CAS  Google Scholar 

  331. European Association for the Study of the Liver (EASL) (1999) (ed) EASL International Consensus Conference on Hepatitis C. Paris: Consensus statement. J Hepatol 30(5):956–961

    Google Scholar 

  332. Fischl M, Richman D, Grieco M et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with Aids and Aids-related complex: A double-blind, placebo-controlled trial. N Engl J Med 317:185–191

    Article  PubMed  CAS  Google Scholar 

  333. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IV (1999) A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 6(5): 387–395

    Article  PubMed  CAS  Google Scholar 

  334. Gubareva LV, Matrosovich MN, Brenner MK et al. (1998b) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178(5) 1257–1262

    Article  PubMed  CAS  Google Scholar 

  335. Gubareva LV, McCullers JA, Bethell RC et al. (1998a) Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 178(6): 1592–1596

    Article  PubMed  CAS  Google Scholar 

  336. Hartmann G, Bidlingmaier M, Tschöp K et al. (1998) Antisense-Oligonukleotide —Nukleinsäuren zur gezielten Synthesehemmung krankheitsfördernder Proteine. Dtsch Ärztebl 95:A-1524-1530 [Heft 24]

    Google Scholar 

  337. Hayden FG, Atmar RL, Schilling M et al. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336–1343

    Article  PubMed  CAS  Google Scholar 

  338. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 345(20):1452–1457

    Article  PubMed  CAS  Google Scholar 

  339. Johnston SL (2002) Anti-influenza therapies (mini review). Virus Res 82 (2002)147–152

    PubMed  CAS  Google Scholar 

  340. Jubin R, Murray MG, Howe AY, Butkiewicz N, Hong Z, Lau JY (2000) Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. J Infect Dis 181(1):331–334

    Article  PubMed  CAS  Google Scholar 

  341. Kearns GL, Abdel-Rahman SM, James LP, Blowey DL, Marshall JD, Wells TG, Jacobs RF (1999) Pediatric Pharmacology Research Unit Network: Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob Agents Chemother 43 (3): 634–638

    PubMed  CAS  Google Scholar 

  342. Lange CG, Stelbrink H-J, van Lunzen J (2002) Indikationen zur Therapie der HIV-Infektion. Dtsch Arztebl 99:A 570-576 [Heft 9]

    Google Scholar 

  343. Larder BA, Kemp SD (1989b) Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT). Science 246:1155–1158

    Article  PubMed  CAS  Google Scholar 

  344. Linde A (2001) The importance of specific virus diagnosis and monitoring for antiviral treatment (review). Antiviral Res 51(2): 81–94

    Article  PubMed  CAS  Google Scholar 

  345. Maag D, Castro C, Hong Z, Cameron CE (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276(49): 46094–46098

    Article  PubMed  CAS  Google Scholar 

  346. Manns M (1999) Europäischer Konsens zu Hepatitis C: Epidemiologie, Diagnose und Therapie. Dtsch Ärztebl 96:A-3252 [Heft 50]

    Google Scholar 

  347. Martin DF, Sierra-Madero J, Walmsley S et al. (2002) A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346:1119–1126

    Article  PubMed  CAS  Google Scholar 

  348. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333(17):1099–1105

    Article  PubMed  CAS  Google Scholar 

  349. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167–1170

    Article  PubMed  CAS  Google Scholar 

  350. Monto AS, Fleming DM, Henry D et al. (1999) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 180(2):254–261

    Article  PubMed  CAS  Google Scholar 

  351. Mousavi-Jazi M, Schloss L, Drew WL et al. (2001) Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol. 23(1–2):1–15

    Article  PubMed  CAS  Google Scholar 

  352. Mulamba GB, Hu A, Azad RF et al. (1998) Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob Agents Chemother 42(4):971–973

    PubMed  CAS  Google Scholar 

  353. Mutimer D (2001) Hepatitis B virus infection: resistance to antiviral agents. J Clin Virol 21:239–242

    Article  PubMed  CAS  Google Scholar 

  354. Naesens L, De Clercq E (2001) Recent developments in herpesvirus therapy (review). Herpes 8(1):12–16

    PubMed  CAS  Google Scholar 

  355. Newell ML (2001) Prevention of mother-to-child transmission of HIV: challenges for the current decade. Bull World Health Organ. 79(12):1138–1144

    PubMed  CAS  Google Scholar 

  356. Peggs KS, Preiser W, Kottaridis PD et al. (2000) Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapyfor cytomegalovirus after allogeneic transplantation. Br J Haematol 2000 Dec 111(3):782–790

    Article  CAS  Google Scholar 

  357. Perry CM, Balfour JA (1999) Fomivirsen. Drugs 57(3):375–380

    Article  PubMed  CAS  Google Scholar 

  358. Pillay D (1998) Emergence and control of resistance to antiviral drugs in herpes viruses, hepatitis B virus, and HIV. Commun Dis Public Health 1:5–13

    PubMed  CAS  Google Scholar 

  359. Pillay D, Emery VC, Mutimer D, Ogilvie MM, Carman W, Mutton K, Wreghitt T, Westmoreland D, Breuer J, Zuckerman M on behalf of the Public Health Laboratory Service (PHLS) Advisory Committee on Virology (2002) Guidelines for laboratory monitoring of treatment of persistent virus infections. J Clin Virol 25:73–92

    Article  PubMed  CAS  Google Scholar 

  360. Pillay D, Zambon M (1998) Antiviral drug resistance. BMJ 317:660–662

    PubMed  CAS  Google Scholar 

  361. Preiser W, Berger A, Doerr HW (2000) Neue Ansätze in der Therapie viraler Erkrankungen. Dtsch Ärzteblatt 97:A 3433–3439 [Heft 50]

    Google Scholar 

  362. Preiser W, Bräuninger S, Schwerdtfeger R et al. (2001) Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 20, 1-2:59–70

    Article  Google Scholar 

  363. Safrin S, Cherrington J, Jaffe HS (1997) Clinical uses of cidofovir. Rev Med Virol 7:145–156

    Article  PubMed  CAS  Google Scholar 

  364. Schiff GM, Sherwood JR (2000) Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 181:20–26

    Article  PubMed  CAS  Google Scholar 

  365. Schilling M, Povinelli L, Krause P (1998) Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 16:1771–1774

    Article  PubMed  CAS  Google Scholar 

  366. Stanberry L, Cunningham A, Mertz G et al. (1999) New developments in the epidemiology, natural history and management of genital herpes (review). Antiviral Res 42(1):1–14

    Article  PubMed  CAS  Google Scholar 

  367. Stürmer M (2001) Korrelaton von Genotyp und phänotypischer Resistenz gegen Reverse Transkriptase-Inhibitoren bei HIV-1. In: Cinatl J Jr, Doerr HW, Gröschel B (Hrsg) Wege zur Aufklärung der Therapieresistenz bei Erkrankungen durch HIV-Infektion: Virale und zelluläre Faktoren. Pabst Science Publishers, Lengerich, S 81–160

    Google Scholar 

  368. Summers J, Mason WS (1982) Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29(2):403–415

    Article  PubMed  CAS  Google Scholar 

  369. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 Protein. Science 285(5424):107–110

    Article  PubMed  CAS  Google Scholar 

  370. The MIST (Management of Influenza in the Southern Hemisphere Trialists) study group (1998) (ed) Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352:1877–1881

    Google Scholar 

  371. Tossing G (2001) New developments in interferon therapy. EurJ Med Res 6(2):47–65

    CAS  Google Scholar 

  372. Trautwein C, Manns MP (2001) Antivirale Therapie der chronischen Virushepatitis. Internist 42:913–923

    Article  PubMed  CAS  Google Scholar 

  373. Varghese JN, Smith PW, Sollis SL et al. (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6(6):735–746

    Article  PubMed  CAS  Google Scholar 

  374. Vogel JU, Scholz M, Cinatl J Jr (1997) Treatment of cytomegalovirus diseases. Intervirology 40(5–6):357–367

    Article  PubMed  CAS  Google Scholar 

  375. Weber, Stürmer M, Preiser W (2002) Grundlagen der Therapie. In: Doerr HW, Gerlich HW (Hrsg) Medizinische Virologie: Grundlagen, Diagnostik und Therapie virologischer Krankheitsbilder (Lehrbuch), 1. Aufl, Kap. 7. Thieme, Stuttgart New York, S 100–115

    Google Scholar 

  376. Webster A, Boyce M, Edmundson S, Miller I (1999) Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 36, Suppl 1:51–58

    Article  Google Scholar 

  377. Wutzler P, Doerr HW (1998) Antivirale Therapie des Zoster. Dtsch Ärzteblatt 95:A-95-97 [Heft 3]

    Google Scholar 

  378. Wutzler P, Petersen EE, Doerr HW et al. (1999) Der Herpes genitalis. Dtsch Ärzteblatt 96:A-2358-2364 [Heft 38]

    Google Scholar 

  379. Younossi ZM, Perrillo RP (1999) The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 19 Suppl 1:95–102

    Google Scholar 

  380. Zoulim F (2001) Detection of hepatitis B virus resistance to antivirals. J Clin Virol 21:3–253

    Article  Google Scholar 

  381. Zoulim F, Trepo C (1999) New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology 42(2–3):125–144

    Article  PubMed  CAS  Google Scholar 

  382. Aarden LA, Brunner TK, Cerottini JC et al. (1979) Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol 123:2928–2929

    CAS  Google Scholar 

  383. Callard RE, Gearing AJH (1994) TNF α. The molecule and the TNF receptors. In: The cytokine facts book. Academic Press, Harcourt&Brace, London, pp 241–246

    Google Scholar 

  384. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147

    PubMed  CAS  Google Scholar 

  385. Heaney ML, Golde DW (1996) Soluble cytokine receptors. Blood 87:847–857

    PubMed  CAS  Google Scholar 

  386. Höffler D, Shah PM (1996) C-reaktives Protein — die diagnostische Reichweite. Thieme, Stuttgart New York

    Google Scholar 

  387. Ibelgaufts H (1995) Dictionary of cytokines. VCH, Weinheim

    Google Scholar 

  388. Küster H, Weiss M, Willeitner AE et al. (1998) Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet 325:1271–1277

    Article  Google Scholar 

  389. Lovell DJ et al. (2000) Etanercept in children with polyarticular juvenile rhematoid arthritis. N Engl J Med 342:763–769

    Article  PubMed  CAS  Google Scholar 

  390. Maini R et al. (1999) Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354:1932–1939

    Article  PubMed  CAS  Google Scholar 

  391. Mathers NJ, Pohlandt F (1987) Diagnostic audit of C-reactive protein in neonatal infection. Eur J Pediatr 146:147–151

    Article  PubMed  CAS  Google Scholar 

  392. Messer J, Eyer D, Donato L, Gallati H, Matis J, Simeoni U (1996) Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pediatr 129:574–580

    Article  PubMed  CAS  Google Scholar 

  393. Metcalf D (1988) The molecular control of blood cells. Harvard University Press, Cambridge (USA)

    Google Scholar 

  394. Metcalf D (1994) Thrombopoetin — at last. Nature (London) 369:519–520

    Article  CAS  Google Scholar 

  395. Nelson S et al. and the CAP Study Group (1998) A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 178:1075–1080

    Article  PubMed  CAS  Google Scholar 

  396. Present DH, Rutgeerts P, Targan S et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  PubMed  CAS  Google Scholar 

  397. Sieff CA, Nathan DG (1993) The anatomy and physiology of hematopoiesis. In: Nathan DG, Oski FA (eds) Hematology of Infancy and Childhood, 4th edn. Saunders, Philadelphia, pp 156–215

    Google Scholar 

  398. Thomson A (ed) (1998) The cytokine handbook, 3rd edn. Academic Press, London New York

    Google Scholar 

  399. Volk HD, Keyßer G, Burmester GR (1998) Zytokine und Zytokin-Rezeptoren. In: Thomas L (Hrsg) Labor und Diagnose, 5. Aufl. TH Books, Frankfurt am Main

    Google Scholar 

  400. Weiss M, Belohradsky BH (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF): a variety of possible applications in clinical medicine. Infection 20:S81–S83

    Article  PubMed  Google Scholar 

  401. Weite K, Dale D (1996) Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol 72:158–165

    Article  Google Scholar 

  402. Wheeler AP, Bernard GR (1999) New aspects in the treatment of sepsis. N Engl J Med 340:207–213

    Article  PubMed  CAS  Google Scholar 

  403. Arya SC (1999) Global warming and the performance of drugs used to treat parasitic and other diseases. Ann Trop Med Parasitol 93:207–208

    Article  PubMed  CAS  Google Scholar 

  404. Ballereau F et al. (1997) Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. Am J Trop Med Hyg 57:31–36

    PubMed  CAS  Google Scholar 

  405. Bessieres MH et al. (2001) Neonatal screening for congenital toxoplasmosis in a cohort of 165 women infected during pregnancy and influence of in utero treatment on the results of neonatal tests. Eur J Obstet Gynecol Reprod Biol 94:37–45

    Article  PubMed  CAS  Google Scholar 

  406. Brøsen K (1998) Differences in interactions of SSRIs. Intern Clin Psychopharmacol 13 (Suppl 5):S45–S47

    Google Scholar 

  407. Capson TL et al. (1996) A new paradigm for drug discovery in tropical rainforests. Nat Biotechnol 14:1200–1201

    Article  PubMed  CAS  Google Scholar 

  408. Cestari SC et al. (2000) Oral treatment of crusted scabies with ivermectin: report of two cases. Pediatr Dermatol 17:410–414

    Article  PubMed  CAS  Google Scholar 

  409. Dasonneville L et al. (2000) Cytotoxicity and cell cycle effects on the plant alkaloids cryptolepine and neocryptolepine: relation to druginduced apoptosis. Eur J Pharmacol 409:9–18 Gelbe Liste: http://www.gelbe-liste.de/index.htm

    Article  Google Scholar 

  410. Hofheinz W et al. (1994) Ro42-1611: (arteflene), a new effective antimalarial: chemical structure and biological activity. Trop Med Parasitol 45:261–265

    PubMed  CAS  Google Scholar 

  411. Kirby GC (1996) Medicinal plants and the control of parasites. Trans Roy Soc Trop Med Hyg 90:605–609

    Article  PubMed  CAS  Google Scholar 

  412. Le Bras J, Durand R (2001) Aspects moleculaires de la résistance aux antifolates et à la chloroquine chez P. falciparum. Ann Pharm Fr 59:85–92

    PubMed  Google Scholar 

  413. Leitch GJ et al. (2001) Role of P-glycoprotein in the course and treatment of Encephalitozoon microsporidiosis. Antimicrob Agents Chemother 45:73–78

    Article  PubMed  CAS  Google Scholar 

  414. Liu LX et al. (1996) Antiparasitc drugs. N Engl J Med 334:1178–1184

    Article  PubMed  CAS  Google Scholar 

  415. Rassi A et al. (2000) Chagas’ heart disease. Clin Cardiol 23:883–889

    Article  PubMed  Google Scholar 

  416. Veeken H, Pécoul B (2000) Drugs for neglected diseases: a bitter pill. Trop Med Intern Health 5:309–311

    Article  CAS  Google Scholar 

  417. Wang CC (1997) Validating targets for antiparasite chemotherapy. Parasitol 114:S31–S44

    Google Scholar 

  418. White AC (2000) The disappearing arsenal of antiparasitic drugs. N Engl J Med 343:1273–1274

    Article  PubMed  Google Scholar 

  419. Whitfield PJ (1996) Medicinal plants and the control of parasites. Novel anthelmintic compounds and molluscicides from medical plants. Trans R Soc Trop Med Hyg 90:596–600

    Article  PubMed  CAS  Google Scholar 

  420. Zinanda NY (2000) The effect of ivermectin on Cryptosporidium parvum in experimentally infected rat. J Egypt Soc Parasitol 30:747–752

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gabriel-Max-Str. 43, 81545, München, Deutschland

    Prof. Dr. Dr. Dr. hc. mult. Adam D.

  2. Westendallee 112, 14052, Berlin, Deutschland

    Prof. Dr. Christ W.

  3. Zentrum für Kinderheilkunde, Allgemeine Pädiatrie, Klinikum der Joh.-Wolfg.-Goethe-Universität, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Deutschland

    Prof. Dr. Hofmann D.

  4. Interkantonale Kontrollstelle für Heilmittel (IKS), Erlachstr. 8, 3000, Bern 9, Schweiz

    Dr. Kemmler H.

  5. Institut für Tropenmedizin, Universität Tübingen, Keplerstr. 15, 72074, Tübingen, Deutschland

    Prof. Dr. Knobloch J.

  6. Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Franz-Josef-Strauß Allee 11, 93053, Regensburg, Deutschland

    Prof. Dr. Lehn N.

  7. Zentralbereich für Krankenhaushygiene, Universität Aachen, Pauwelstr. 30, 52074, Aachen, Deutschland

    Priv.-Doz. Dr. S. W. Lemmen

  8. Zentralklinik Emil von Behring, Zum Heckeshorn 33, 14109, Berlin, Deutschland

    Prof. Dr. Lode H.

  9. Zentralbereich für Krankenhaushygiene, Universität Aachen, Pauwelstr. 30, 52074, Aachen, Deutschland

    Priv.-Doz. Dr. Mertens R.

  10. Urologische Klinik, St.-Elisabeth-Krankenhaus GmbH, St.-Elisabeth-Str. 23, 94315, Straubing, Deutschland

    Prof. Dr. K. G. Naber

  11. Institut für Med. Virologie, Zentrum der Hygiene im Klinikum der Joh.-Wolfg.-Goethe-Universität, Paul-Ehrlich-Str. 40, 60596, Frankfurt am Main, Deutschland

    Dr. Preiser W.

  12. Institut für Klinische Pharmakologie und Toxikologie der FU, Garystraße 5, 14195, Berlin, Deutschland

    Dr. Riecke K.

  13. Med. Klinik, Charité, Campus Mitte Onkologie, Humboldt-Universität, Schumannstr. 20/21, 10117, Berlin, Deutschland

    Prof. Dr. Ruhnke M.

  14. Institut für Klin. Pharmakologie und Toxikologie, FU Berlin, Klinikum Benjamin Franklin, Garystr. 5, 14195, Berlin, Deutschland

    Prof. Dr. Stahlmann R.

  15. Urol. Abt. Klinik Wildetal, Mühlenstr. 8, 34537, Bad Wildungen, Deutschland

    Dr. Vahlensieck W.

  16. Pädiatrische Klinik, Kinderkrankenhaus Riehl, Kliniken der Stadt Köln, Amsterdamer Str. 59, 51058, Köln, Deutschland

    Priv.-Doz. Dr. Weiß M.

Authors
  1. Prof. Dr. Dr. Dr. hc. mult. Adam D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Christ W.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Hofmann D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. Kemmler H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. Knobloch J.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr. Lehn N.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Priv.-Doz. Dr. S. W. Lemmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Prof. Dr. Lode H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Priv.-Doz. Dr. Mertens R.
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Prof. Dr. K. G. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dr. Preiser W.
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dr. Riecke K.
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Prof. Dr. Ruhnke M.
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Prof. Dr. Stahlmann R.
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Dr. Vahlensieck W.
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Priv.-Doz. Dr. Weiß M.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dr. von Haunersches Kinderspital der Ludwig-Maximilians-Universität, Lindwurmstr. 4, 80337, München, Deutschland

    D. Adam

  2. Institut für Medizinische Virologie des Klinikums, Johann-Wolfgang-Goethe-Universität Frankfurt/M., Paul-Ehrlich-Str. 40, 60596, Frankfurt, Deutschland

    H. W. Doerr

  3. Westpfalz-Klinikum, Medizinische Klinik I, Hellmut Hartert Str. 1, 67653, Kaiserslautern, Deutschland

    H. Link

  4. Zentralklinik Emil von Behring Pneumologische Abteilung I, Zum Heckeshorn 33, 14109, Berlin, Deutschland

    H. Lode

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

D., A. et al. (2004). Antiinfektive Therapie. In: Adam, D., Doerr, H.W., Link, H., Lode, H. (eds) Die Infektiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18577-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18577-9_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00075-4

  • Online ISBN: 978-3-642-18577-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation